Digital Sponsored The devil’s in the e-detail: what HCPs really want from you Overview Communication; we all do it, it is a critical part of effective business practice and in this pharma is no exception.
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.